DBV Technologies S.A. (DBVT): Capital Expenditures

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2020-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$532.0K

Year ended 2025-12-31

-11.0%

3-year compound annual growth

-28.2%

5-year compound annual growth

2019-12-31 Capital Expenditures (USD) 2025-12-31

Period ended	Capital Expenditures	Change YoY	Source filing
2025-12-31	$532.0K	-77.2%	2026-03-26, From 2025-01-01
2024-12-31	$2.34M	+245.3%	2026-03-26, From 2024-01-01
2023-12-31	$677.0K	-10.2%	2025-04-11, From 2023-01-01
2022-12-31	$754.0K	-17.1%	2024-03-07, From 2022-01-01
2021-12-31	$910.0K	-67.4%	2023-03-02, From 2021-01-01
2020-12-31	$2.79M	n/c	2022-03-09, From 2020-01-01
2019-12-31	$5.57M	n/a	2021-03-17, From 2019-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Capital Expenditures	Change YoY
DBV Technologies S.A. (DBVT)	2025-12-31	$532.0K	-77.2%
Zeo ScientifiX, Inc. (ZEOX)	2025-10-31	$23.0K	n/a
Fate Therapeutics Inc (FATE)	2025-12-31	$5.95M	+715.5%
Prime Medicine, Inc. (PRME)	2025-12-31	$4.53M	-37.9%
Ocugen, Inc. (OCGN)	2025-12-31	$185.0K	-94.5%
CG Oncology, Inc. (CGON)	2025-12-31	$134.0K	-42.7%
CRISPR Therapeutics AG (CRSP)	2025-12-31	$914.0K	-51.9%
Surrozen, Inc. (SRZN)	2025-12-31	$128.0K	+392.3%
Taysha Gene Therapies, Inc. (TSHA)	2025-12-31	$738.0K	+97.3%

Compare DBVT, ZEOX, FATE, PRME side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗